Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

April 24, 2025 Sanofi's quarterly profit boosted by Dupixent and newer drugs; forecast unchanged France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Sanofi SAN0.13%increase; green up pointing triangle posted better-than-expected sales and profit in the first quarter on higher demand for its key drugs and vaccines. The French pharmaceutical ...

Sales rose 11% to 9.895 billion euros on higher demand for its key drugs and vaccines and a favorable base of comparison. Analysts expected business operating profit of 2.68 billion euros on sales of ...

And Sanofi solicits new ideas from employees. It even holds an annual Planet Care Challenge offering rewards to workers with ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to ...

COPD represents a significant opportunity for Sanofi and its U.S. drug partner Regeneron as Dupixent is the first biologic approved for the condition, which is the fourth-leading cause of death in ...